Merus N.V.
MRUSDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
Petosemtamab
Head and Neck Squamous Cell Carcinoma
Investigator's Choice
Head and Neck Squamous Cell Carcinoma
MCLA-158
Advanced/Metastatic Solid Tumors
Zenocutuzumab
Breast Cancer Metastatic
MCLA-129
Non-Small Cell Lung Cancer Metastatic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Petosemtamab | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
Investigator's Choice | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
MCLA-158 | Phase 2 | Advanced/Metastatic Solid Tumors | - | - |
Zenocutuzumab | Phase 2 | Breast Cancer Metastatic | - | - |
MCLA-129 | Phase 2 | Non-Small Cell Lung Cancer Metastatic | - | - |
Head and Neck Squamous Cell Carcinoma
2 drugs in this indication
Breast Cancer Metastatic
1 drug in this indication
Advanced/Metastatic Solid Tumors
1 drug in this indication
Non-Small Cell Lung Cancer Metastatic
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)